Abstract Library

#903 Health-Related Quality-of-Life (HRQoL) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) Treated with Everolimus (EVE): Results from an Open-label, Phase IIIb, Multicenter, Expanded Access Program (EAP)

Introduction: NET is associated with a considerable HRQoL burden.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Pavel M, Unger N, Borbath I, Ricci S, Hwang T,

Keywords: everolimus, QoL, NET,

#887 Detection Limitation of Occult NET Using Gallium-68 Dotatoc Scan Plus FDG PET

Introduction: The modalities detection of gastroenteropancreatic neuroendocrine tumors (GEP-NET) includes sonogram, abdominal CT and MRI, but the detection rate is limited. Iodium-111 Octreotide scan is another choice. Ga-68 Dotatoc scan is very rapid and more sensitive than Octreoscan. The Ga-68 Dotatoc scan plus FDG-PET is useful for detecting active NETs.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Hwang T

Authors: Chen S, Yen C, Hwang T,

Keywords: GEP-NET, Ga-68 Dotatoc scan,

#633 Clinical and Prognostic Features of Neuroendocrine Tumor of Unknown Primary Site

Introduction: Neuroendocrine tumors of unknown primary site (NET UPS) are rare and heterogenous tumors with poor prognosis. There is little information available on the treatment and prognosis.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Shim H

Authors: Shim H, Kim D, Hwang J, Lee K, Cho S,

Keywords: neuroendocrine tumor, unknown primary site,

#428 Clinical Manifestations of Patients with Pancreatic ß Cells Hyperplasia

Introduction: Pathologic hyperplasia of pancreatic endocrine cells is uncommon. ß cell hyperplasia contributes to persistent hyperinsulinemic hypoglycemia. The manifestations of patients with pancreatic ß cells hyperplasia are variable and their preop. diagnosis is difficult.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hwang T, Hsu J, Shan Y,

Keywords: ß cell hyperplasia,

#288 An Observational Registry Collecting Data on Gastroenteropancreatic Neuroendocrine Tumor Patients (GEP-NET Registry) in the Middle East and Asia

Introduction: NET awareness is low in the Middle East and Asia. This registry of GEP NET patients will capture reported outcomes from physicians in clinical practice who treat patients with GEP NET.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Hwang T, Lang B, Ovartlarnporn B, Park Y, Katta J,

Keywords: gastroenteropancreatic neuroendocrine tumor, GEP NET, registry, observational study,